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Objective—To determine healthcare-associated infection (HAI) prevalence in nine Jacksonville, 
FL hospitals, evaluate the performance of proxy indicators for HAIs, and refine methodology in 
preparation for a multi-state survey.
Design—Point prevalence survey.
Patients—Acute care inpatients of any age.
Methods—HAIs were defined using National Healthcare Safety Network criteria. In each facility 
a trained Primary Team (PT) of infection prevention (IP) staff performed the survey on 1 day, 
reviewing records and collecting data on a random sample of inpatients. PTs assessed patients 
with ≥1 proxy indicator (abnormal white blood cell count, abnormal temperature, or antimicrobial 
therapy) for the presence of HAIs. An external IP expert team collected data from a subset of 
patient records reviewed by PTs to assess proxy indicator performance and PT data collection.
Results—Of 851 patients surveyed by PTs, 51 had ≥1 HAI (6.0%, 95% confidence interval 4.5–
7.7%). Surgical site infections (n=18), urinary tract infections (n=9), pneumonia (n=9), and 
bloodstream infections (n=8) accounted for 75.8% of 58 HAIs detected by PTs. Staphylococcus 
aureus was the most common pathogen, causing 9 HAIs (15.5%). Antimicrobial therapy was the 
most sensitive proxy indicator, identifying 95.5% of patients with HAIs.
Conclusions—HAI prevalence in this pilot was similar to that reported in the 1970s from 
CDC’s Study on the Efficacy of Nosocomial Infection Control. Antimicrobial therapy was a 
sensitive screening variable with which to identify higher-risk patients and reduce data collection 
burden. Additional work is needed on validation and feasibility to extend this methodology to a 
national scale.
Background
Significant progress has been made in recent years to implement effective infection 
prevention strategies in U.S. healthcare facilities and reduce the occurrence of some 
preventable healthcare-associated infections (HAIs). Despite this progress, a recent analysis 
of HAI burden and cost using data reported to the Centers for Disease Control and 
Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) indicates that HAIs 
remain a serious public health problem in the United States.1 To develop, target, and 
implement effective HAI surveillance and prevention strategies in U.S. hospitals, a full 
understanding is needed of the types of HAIs and the affected patient populations.
Single- and small multi-center prevalence surveys have been utilized in U.S. hospitals since 
the 1960s as a simple method by which to describe HAI burden and evaluate the 
effectiveness of surveillance programs.2–5 In the earliest of these studies, performed at 
Boston City Hospital, 13.4% of patients surveyed over a one-week period had an infection 
that was not present on admission to the hospital.2 In a 6-hospital, CDC-run survey 
conducted in 1965–1966, the adjusted nosocomial infection rate was 3.5 per 100 
discharges.4 These early efforts informed the development and implementation of the 
CDC’s National Nosocomial Infections Surveillance (NNIS) system and the Study on the 
Efficacy of Nosocomial Infection Control (SENIC) in the 1970s. SENIC was a $27 million, 
multi-phase effort in which teams of trained CDC data abstractors reviewed medical records 
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of 169,526 patients from a stratified random sample of 338 hospitals over a one-year 
period.6,7 In the SENIC project, 5.23% of hospitalized patients acquired one or more HAIs.7
Hospital-wide surveillance in selected hospitals continued in the NNIS system until 1996. At 
that time, in response to increasing demands on infection control personnel, NNIS hospitals 
moved from hospital-wide surveillance toward targeted surveillance in high-risk inpatient 
areas such as intensive care units. In 2002, CDC epidemiologists used NNIS data from 
1990–2002 and estimated the total number of HAIs in the United States to be 1.7 million, or 
4.5 infections per 100 admissions.8
CDC’s current HAI surveillance system, the NHSN, replaced NNIS in 2005; over 4500 
healthcare facilities across the country report some device- and procedure-associated HAIs 
in selected hospital locations to NHSN. However, most facilities do not report data on all 
HAI types present in all acute care patient populations. Therefore, measurements of the 
magnitude of all types of HAIs occurring hospital-wide, needed to inform decisions by local 
and national policy makers and by hospital infection control personnel regarding appropriate 
targets and strategies for HAI surveillance and prevention, are not currently readily available 
on a national scale from NHSN. Such estimates can be obtained in a resource-effective way 
through point prevalence surveys; these surveys can also be repeated at regular intervals to 
assess HAI and antimicrobial use trends over time.9 Multiple countries have used prevalence 
surveys to estimate the scope of their HAI problems.10–32 Some investigators have evaluated 
screening approaches (e.g., using proxy indicators to identify patients most likely to have 
HAIs) to reduce the number of patients needing to be fully evaluated, therefore providing a 
more feasible approach to conducting large-scale prevalence surveys.33,34
To inform the development of a large, multi-state U.S. HAI point prevalence survey, we 
conducted a pilot survey in collaboration with the Florida Department of Health and nine 
acute care hospitals in Jacksonville, Florida. The primary objectives of this pilot survey were 
to: 1) estimate HAI prevalence in a random sample of inpatients; 2) describe the distribution 
of HAIs by major infection site and causative pathogens; 3) evaluate the performance of 
proxy indicators in identifying patients with HAIs; and 4) evaluate the accuracy and 
reliability of prevalence survey data collection.
Methods
Survey design, hospitals and patient selection
Nine acute care hospitals located in the Jacksonville, FL metropolitan area volunteered to 
participate in the survey. Following approval by the CDC Institutional Review Board (IRB) 
and by IRBs of participating hospitals, each hospital conducted the survey on a single day 
(Tuesday through Thursday) in August 2009. The Florida Department of Health determined 
the survey to be a non-research surveillance activity.
Patients of any age hospitalized in acute care inpatient units were eligible for inclusion. 
Patients were not eligible if they were in non-acute care or outpatient areas; in psychiatric 
units, rehabilitation units or skilled nursing units; in the emergency department; or on 
observation status in an acute care inpatient unit with a length of stay <24 hours at the time 
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of the survey. The hospital census on the morning of the survey was used to generate a 
random sample of eligible patients to be surveyed.
Training and data collection
Data were collected on paper forms by infection preventionists (IPs) and other designated 
personnel working in their own hospitals; these hospital-based teams were called the 
Primary Teams (PTs). Prior to the survey dates, PTs participated in approximately 6 hours 
of training in NHSN HAI terms and definitions and survey procedures. PTs completed most 
of their data collection activities on the survey date, but were permitted an additional 14 
days after the survey date to complete data collection when necessary, as long as all data 
collection remained restricted to information present (or cultures collected) on or prior to the 
survey date. In addition to limited demographic and clinical information, data collection 
included information on the presence of proxy HAI indicators on the survey date or the 
calendar day prior to the survey date (white blood cell count <4,000 cells/mm3 or ≥12,000 
cells/mm3 [≥15,000 cells/mm3 for infants ≤1 year]; temperature >38°C for all ages or <36°C 
for infants ≤1 year; and whether the patient was on antimicrobial agents).
To identify active HAIs, PTs performed comprehensive medical record review for those 
patients with ≥1 proxy indicator. HAIs were defined according to NHSN criteria,36 and were 
identified as being active if signs and symptoms of the HAI were present on the survey date, 
or signs and symptoms of the HAI were present prior to the survey date and the patient was 
still receiving antimicrobial treatment for that HAI on the survey date. PTs reported only 
those HAIs that were attributed to their own hospitals; active HAIs detected on the survey 
date that were attributed to other healthcare facilities were not reported.
Paper forms labeled with hospital and patient identification codes were returned to CDC for 
analysis. Identification codes (called CDC ID codes) were created for the survey and 
contained no personal identifiers. The links between CDC ID codes and hospital and patient 
identifiers were known only to each individual hospital.
Evaluation Team assessment of proxy indicator performance and PT surveillance
An Evaluation Team (ET), composed of 4 experienced IPs who were from outside of 
Jacksonville, FL and were serving as expert reviewers, performed an assessment of proxy 
indicator performance and an evaluation of the data collected by the PTs. The ET attempted 
to perform comprehensive medical record review (regardless of the presence of proxy 
indicators) for every other patient on the PTs’ lists of patients randomly selected for 
inclusion in the survey. Due to time constraints, the ET reviewed records of a 40% subset of 
the patients reviewed by the PTs. ET members traveled to each of the hospitals on the 
survey dates and performed assessment activities in parallel with PT members. ET members 
also completed HAI criteria worksheets for those patients determined to have HAIs. PT 
members provided the ET with brief orientations to the hospitals and medical record systems 
on the mornings of the survey dates. Other than these orientations, the ET and PTs operated 
independently and were not permitted to discuss or exchange information regarding 
surveyed patients.
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Following CDC’s review of the data, PT members re-reviewed medical records of patients 
for whom the PT and ET made differing HAI determinations. ET HAI criteria worksheets 
were used to determine how ET HAI determinations were made for discrepant cases, and for 
some discrepancies the ET leader returned to a participating hospital to re-review medical 
records. After completion of these re-reviews a Resolution Team (RT), composed of PT 
members, the ET leader, and Florida Department of Health and CDC prevalence survey 
personnel, was convened. The RT held conference calls with a representative of each PT to 
discuss HAI discrepancies and make decisions regarding correct HAI determinations. The 
RT focused on major discrepancies, defined as discrepancies in which one team determined 
the patient had an HAI and the other team determined the patient did not have an HAI.
Analysis
To estimate the survey sample size, we used the standard sample size formula for random 
samples. Using an estimated HAI prevalence of 10% and a desired precision of ±2% we 
estimated the desired survey sample size to be approximately 864 patients. This total 
estimated sample size was divided between the participating hospitals in a manner 
proportional to each hospital’s average daily census, such that each PT was asked to review 
approximately 33% of its average daily census.
Data were entered into a Microsoft Access 2007 database and analyzed in SAS version 9.2 
(SAS, Inc., Cary, NC) and OpenEpi version 2. Confidence intervals around prevalence 
estimates were generated using the mid-P exact method. A descriptive analysis of HAIs and 
major HAI discrepancies was performed. Sensitivity, specificity, positive and negative 




A total of 857 patients identified by unique CDC ID codes were surveyed by the PTs. Six 
patients were excluded because of data coding errors or incomplete data collection. 
Therefore, 851 patients (47 to 175 patients in each participating hospital) were included in 
the analysis. The median patient age was 54 years (interquartile range [IQR] 33–69 years). 
More than a quarter of all surveyed patients had a device in place on the survey date, had 
undergone an operative procedure during the current hospital admission, or had a previous 
admission to the survey hospital within 3 months prior to the survey date (Table 1).
Prevalence and distribution of HAIs and pathogens identified by PT surveillance
A total of 489 patients (57.5%) had ≥1 proxy HAI indicator and underwent comprehensive 
medical record review by the PTs. PTs detected 58 HAIs in 51 patients; 7 patients had 2 
HAIs each. The prevalence of patients with ≥1 HAI was 6.0% (95% CI 4.5–7.7%). Surgical 
site infection (SSI) was the most common HAI type, accounting for 18 of 58 HAIs (31.0%). 
Ten SSIs (55.6%) were organ/space infections, 4 (22.2%) were deep incisional, and 4 
(22.2%) were superficial incisional infections. Pneumonia (PNEU), urinary tract infection 
(UTI) and bloodstream infection (BSI) were also prevalent, each accounting for >10% of 
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HAIs (Table 2). Overall, these 4 HAI types accounted for 75.8% of all HAIs detected by the 
PTs. Of the 40 non-SSI HAIs, 15 (37.5%) were attributed to non-ICU ward locations, 13 
(32.5%) to critical care units, 4 (10%) to stepdown units, and 4 (10%) to specialty care 
areas. Locations of attribution were missing or unknown for 4 non-SSI HAIs (10%).
Pathogens were reported for 41 HAIs detected by the PTs (70.7%). A single pathogen was 
reported for 34 of 41 HAIs (82.9%), and multiple pathogens were reported for 7 HAIs 
(17.1%). Staphylococcus aureus (SA) was the most common pathogen (9 HAIs, 15.5% of all 
HAIs). Other pathogens reported for ≥1 HAI included Candida species (6 HAIs), 
Pseudomonas aeruginosa (5), coagulase-negative staphylococci (5), Enterococcus species 
(5), Klebsiella pneumoniae (4), Escherichia coli (4), Clostridium difficile (2) and viridans 
streptococci (2).
ET assessment of proxy indicator performance and PT surveillance
The ET reviewed medical records of 340 of the 851 patients surveyed by the PTs (40.0%). 
Among these patients, antimicrobial therapy was the most sensitive proxy indicator, 
detecting 95.5% of patients determined by the ET to have HAIs (Table 3).
The ET detected 24 HAIs, and ≥1 HAI in 22 patients, for a prevalence of 6.5% (95% CI 
4.2–9.5%). Similar to the PTs, SSI was the most common HAI (9/24 HAIs, 37.5%) followed 
by pneumonia (5, 20.8%), BSI (3, 12.5%) and UTI (2, 8.3%). Pathogens were reported for 
18 of the HAIs detected by the ET (75.0%); as for the PT, SA was identified as the most 
common pathogen (6/24 HAIs, 25.0%).
Overall agreement between the PTs and ET on the presence or absence of HAIs was 
moderate at the HAI level (kappa 0.47, 95% CI 0.30–0.64) and at the patient level (kappa 
0.51, 95% CI 0.33–0.69). HAI discrepancies at the patient level were common. Forty-one 
HAIs in 35 patients were detected among the 340 patients surveyed by the PTs and the ET: 
17 were detected only by the PTs, 10 only by the ET, and 14 by both teams. Thirty-two 
discrepancies were detected in these 41 HAIs; 27 of these (84.4%) were major 
discrepancies, where teams disagreed on whether an HAI was present or not (Table 4). HAI 
types that were most common among the major discrepant cases were PNEU (9/27 cases, 
33.3%) and UTI (6/27 cases, 22.2%). Although the PTs and the ET detected similar 
proportions of HAIs that were PNEU and UTI, on the individual patient level there was no 
agreement between the teams on which patients had PNEU or which patients had UTI.
The RT determined that most major discrepancies (21/27, 77.8%) were due to problems 
understanding and/or interpreting NHSN HAI definition criteria. The RT was able to assign 
a correct determination to 26 of 27 major discrepancies (96.3%): 14 (53.8%) were not HAIs 
and 12 (46.2%) were HAIs. Resolution was not achieved for one PNEU case. A modified 
HAI prevalence was calculated using RT determinations for the discrepant cases. Among the 
339 patients for whom there was PT and ET agreement on the presence or absence of HAIs, 
or for whom resolution was achieved, there were 13 patients with HAIs detected by PTs and 
the ET, plus an additional 9 patients with HAIs confirmed through the RT process, yielding 
a prevalence of 6.5% (95% CI: 4.2–9.5%), similar to initial estimates obtained by the PTs 
and the ET.
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In this pilot phase of CDC’s HAI prevalence survey development effort, 6.0% of acute care 
inpatients had ≥1 HAI detected by the PTs—similar to the prevalence of 5.23% reported in 
the SENIC,7 conducted more than 30 years ago, prior to widespread appreciation of HAIs as 
important causes of preventable harm in hospitalized patients. While implementation of 
effective HAI prevention measures in recent years35 might suggest that HAI prevalence 
should have been lower in 2009, there are a number of potential reasons why HAI 
prevalence in this single-city pilot survey is similar to that observed in the 1970s. The 
SENIC included general adult medical and surgical patients and excluded children, 
obstetrical patients (except those undergoing cesarean section), and surgical subspecialty 
patients. It was also designed only to capture HAIs of the 4 major types (UTI, SSI, BSI and 
pneumonia), because at the time these were estimated to account for at least 80% of all 
HAIs.7 Given that not all HAI types were included, it is possible that 5.23% is an 
underestimate of HAI prevalence in the SENIC. In addition, other factors may explain why 
the prevalence does not appear substantially lower in the current survey, conducted in an era 
of increased HAI prevention success: for example, greater severity of illness of acute care 
inpatients, differences in comorbidities of the patient populations under surveillance, and 
improvements in HAI surveillance definitions and detection methods.
While HAI prevalence in the current survey is similar to that reported in SENIC, the 
distribution and rank order of HAIs in this survey is different. SSIs in this survey were the 
most common HAIs detected by the PTs, accounting for almost one-third of all infections. 
This is similar to the 28% prevalence of surgical wound infections in the SENIC, 7 but in 
contrast to the results of an analysis by Klevens and colleagues using NNIS data from 1990–
2002, which showed that just 20% of HAIs were SSIs.8 In both of these previous efforts, 
UTIs were the most common HAI type, accounting for 53% and 36% of all HAIs, 
respectively,7, 8 while in the current survey, UTIs accounted for just 15.5% of all HAIs. The 
exclusion of asymptomatic bacteriuria and funguria from the CDC’s healthcare-associated 
UTI definition in 2009 likely explains in part the relatively lower proportion of HAIs that 
are now found to be UTIs. In addition, increased focus on appropriate use of urinary 
catheters, a major risk factor for healthcare-associated UTI, may also have contributed to the 
lower rank order of UTI in the current survey.
The proportion of HAIs other than the four major types in the current survey was 
approximately 24%, which is similar to that reported in the Klevens analysis.8 It is perhaps 
surprising that gastrointestinal tract infections did not account for a larger proportion of 
HAIs in the current survey, given the increasing incidence of Clostridium difficile infection 
(CDI) in healthcare settings.37, 38 C. difficile was reported as the cause of only 2 GI 
infections in this survey (3.4% of all HAIs), raising the possibility that existing NHSN GI 
definitions, which have not been updated in several years, are not adequately capturing the 
majority of healthcare-associated CDI cases. To address this concern, a specific definition of 
healthcare-associated CDI will be utilized in subsequent phases of CDC’s prevalence 
survey.
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Many of the existing NHSN HAI definitions were developed in the 1990s for use in internal 
quality improvement efforts and reporting to the NNIS system. In some cases, definitions 
are complex and multifaceted, and many are subjective and open to significant interpretation 
by the user. It is not entirely surprising, then, that understanding and/or interpretation of the 
NHSN definitions were the sources of most major discrepancies in HAI determinations. 
Significant interobserver variability has been reported for some of the NHSN HAI 
definitions39, 40; in this survey, the agreement between the PTs and the ET on HAI 
determinations was moderate, with a kappa of approximately 0.5. Not surprisingly, 
pneumonia and UTI cases accounted for many of the major HAI discrepancies. These are 
anecdotally regarded as among the most complex of the HAI surveillance definitions. To 
address this, more training in NHSN terms and definitions has been incorporated into 
subsequent phases of CDC’s HAI prevalence survey development effort. CDC staff are also 
reviewing some of the current NHSN HAI definitions, including BSI, PNEU and SSI, as 
well as aspects of NHSN surveillance methodology, with the goal of making HAI 
surveillance more objective, streamlined, and in some cases automatable through use of 
electronic data capture.
We explored the performance of three proxy indicators in detecting patients with HAIs and 
found that one indicator in particular, antimicrobial therapy, detected almost all patients who 
were determined to have HAIs by the ET. The high sensitivity of antimicrobial therapy is 
likely related to the high prevalence of antimicrobial use in this survey population; 
approximately 46% of patients received antimicrobial therapy on the survey date or the 
calendar day prior to the survey date. We did not have the resources in this pilot to collect 
detailed information on antimicrobial use, but have incorporated this into the next phases of 
the survey. Based on its high sensitivity in identifying patients with HAIs in this pilot, we 
are using antimicrobial therapy as a proxy indicator to reduce the burden of medical record 
review in subsequent phases of survey development.
This pilot survey has several limitations, including its small size and restriction to acute care 
hospitals in a single metropolitan area. The results therefore may not be generalizable to 
other regions or to the United States. Furthermore, training of PT members in NHSN terms 
and definitions was limited, and was not provided for ET members. This may have 
contributed to the interobserver variability that we observed. Due to the single-day nature of 
the individual hospital surveys, PT and ET members were faced with a considerable amount 
of data collection to complete in a short amount of time. ET members had limited time to 
familiarize themselves with each hospital’s medical information system, and at times 
encountered challenges in locating the necessary clinical information in patient medical 
records. We expect these factors also contributed to interobserver variability. We have 
attempted to address these limitations in subsequent phases of the survey development effort 
by 1) increasing the sample size of hospitals and patients; 2) increasing the geographic 
diversity of participating hospitals; 3) changing the data collection procedures so that HAI 
determinations are made through retrospective medical record review; and 4) providing 
enhanced training in NHSN terms and definitions and survey procedures to all data 
collectors involved in the survey.
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The experience gained in this pilot survey has contributed to refinements in methodology 
and training that will improve the quality of CDC’s multistate prevalence survey effort. 
Additionally, this pilot survey effort has contributed to a greater understanding of the 
potential sources of interobserver variability in NHSN surveillance methods. Expansion of 
prevalence assessments to a larger sample of U.S. hospitals and modification of operations 
in response to the lessons learned in this pilot should provide policy makers, public health 
workers, infection preventionists and healthcare providers with HAI and antimicrobial use 
data to inform the development and implementation of targeted surveillance and high-impact 
prevention programs.
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Table 1
Patient Demographic and Clinical Characteristics
Characteristic No. (%) of patients (n = 851)
Sex
 Male 362 (42.5)
 Female 481 (56.5)
 Missing 13 (1.5)
Age category
 <1 year 98 (11.5)
 1–17 years 27 (3.2)
 18–24 years 35 (4.1)
 25–44 years 145 (17.0)
 45–64 years 271 (31.8)
 ≥ 65 years 274 (32.2)
 Missing 1 (0.1)
Hospital locationa on the survey date
 Critical care unit 125 (14.7)
 Stepdown unit 80 (9.4)
 Critical care or stepdown unitb 3 (0.4)
 Specialty care area 35 (4.1)
 Newborn nursery and special care nursery 47 (5.5)
 Ward 553 (65.0)
 Missing 8 (0.9)
Device use on survey date
 Any central line 237 (27.8)
 Peripherally-inserted central catheter 140 (16.5)
 Femoral line 14 (1.6)
 Other central linec 85 (10.0)
 Unspecified central line type 12 (1.4)
 > 1 central line type 13 (1.5)
 Urinary catheter 231 (27.1)
 Ventilator 44 (5.2)
NHSN-defined operative procedured during current hospital admission 252 (29.6)
Previous admission to the survey hospital in 3 months prior to survey date 218 (25.6)
HAI proxy indicators
 White blood cell count abnormalitye 213 (25.0)
 Temperature abnormalityf 80 (9.4)
 Antimicrobial therapy 389 (45.7)
 ≥1 indicators 489 (57.5)
a
As defined by NHSN. Critical care units include level II/III and level III neonatal intensive care units.
b
Patients for whom a single location was not assigned.
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c
Not including femoral lines or peripherally-inserted central catheters.
d
Includes NHSN-defined “Other” (“OTH”) procedures.
e
White blood cell count <4,000 cells/mm3 or ≥12,000 cells/mm3 (≥15,000 cells/mm3 for infants ≤1 year) on the survey date or the calendar day 
prior to the survey date.
f
Temperature >38°C (all ages) or <36°C (infants ≤1 year) on the survey date or the calendar day prior to the survey date.
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Table 2
National Healthcare Safety Network (NHSN) Healthcare-Associated Infections Detected by the Primary 
Teams
NHSN HAI Type (code) No. (%) of HAIs (n = 58)
Surgical site infections (SSI) 18 (31.0)
Pneumonia (PNEU) 9 (15.5)a
Urinary tract infections (UTI) 9 (15.5)b
Bloodstream infections (BSI) 8 (13.8)c
Gastrointestinal infections (GI) 4 (6.9)
Skin and soft tissue (SST) 4 (6.9)
Lower respiratory infections (LRI) 2 (3.4)
Eye, ear, nose, throat, or mouth (EENT) 2 (3.4)
Cardiovascular system (CVS) 1 (1.7)
Central nervous system (CNS) 1 (1.7)
a
Two of 9 infections (22.2%) were ventilator-associated.
b
Five of 9 infections (55.6%) were catheter-associated.
c
Eight of 8 infections (100%) were central line-associated.
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Table 4
Healthcare-associated infection determination major discrepancies and resolution (N=27).
HAI No. PT Determination ET Determination Discrepancy Source(s)a Final RT Determination
1 BSI No HAI Data access; data collection error BSI
2 EENT No HAI Data collection error No HAI
3 GI No HAI Data collection error GI
4 PNEU No HAI Data access No HAI
5 PNEU No HAI HAI definition understanding/interpretation Unresolved
6 PNEU No HAI HAI definition understanding/interpretation No HAI
7 PNEU No HAI HAI definition understanding/interpretation No HAI
8 SSI No HAI Data collection error SST
9 SSI No HAI HAI definition understanding/interpretation No HAI
10 SSI No HAI HAI definition understanding/interpretation No HAI
11 SST No HAI HAI definition understanding/interpretation No HAI
12 SST No HAI HAI definition understanding/interpretation No HAI
13 SST No HAI HAI definition understanding/interpretation No HAI
14 UTI No HAI Data access UTI
15 UTI No HAI HAI definition understanding/interpretation No HAI
16 UTI No HAI HAI definition understanding/interpretation No HAI
17 UTI No HAI HAI definition understanding/interpretation UTI
18 No HAI CVS HAI definition understanding/interpretation CVS
19 No HAI PNEU HAI definition understanding/interpretation PNEU
20 No HAI PNEU HAI definition understanding/interpretation PNEU
21 No HAI PNEU HAI definition understanding/interpretation PNEU
22 No HAI PNEU HAI definition understanding/interpretation No HAI
23 No HAI PNEU HAI definition understanding/interpretation PNEU
24 No HAI REPR HAI definition understanding/interpretation REPR
25 No HAI SSI HAI definition understanding/interpretation; data 
collection error
No HAI
26 No HAI UTI HAI definition understanding/interpretation No HAI
27 No HAI UTI HAI definition understanding/interpretation UTI
PT = Primary Team, ET = Evaluation Team, RT = Resolution Team, HAI = healthcare-associated infection, BSI = bloodstream infection, EENT = 
ears/eyes/nose/mouth/throat infection, GI = gastrointestinal infection, PNEU = pneumonia, SSI = surgical site infection, SST = skin and soft tissue 
infection, UTI = urinary tract infection, CVS = cardiovascular system infection, REPR = reproductive tract infection.
a
Possible sources included the following: 1) data access, in which the ET did not have access to test results available to the PTs (for example, 
results of cultures collected on the survey date); 2) data collection error, in which information necessary to make an HAI determination was clearly 
present in the medical record but was not recognized or recorded by the data collector; 3) HAI definition understanding/interpretation, in which 
data collectors lacked awareness or understanding of the criteria necessary to make NHSN HAI determinations. More than one source could be 
identified for any given HAI discrepancy.
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